Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02049164 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of AR08 for the Treatment of Vasomotor Symptoms (VMS)
A Phase 2 study, sponsored by Arbor Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT02049164 is a Phase 2 study that was terminated before completion, run by Arbor Pharmaceuticals. The registered enrollment target is 32 participants.
The verdict
NCT02049164, a Phase 2 study, was terminated before completion, sponsored by Arbor Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effective dose or dose range of AR08 in the treatment of VMS in menopausal females.
Interventions
- DRUG Placebo
- DRUG AR08
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02049164
The ClinicalTrials.gov registry entry for NCT02049164 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arbor Pharmaceuticals, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02049164 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02049164 about?
NCT02049164 is a clinical study titled "Safety and Efficacy Study of AR08 for the Treatment of Vasomotor Symptoms (VMS)". The purpose of this study is to determine the effective dose or dose range of AR08 in the treatment of VMS in menopausal females.
What is the current status of trial NCT02049164?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2014-01. Estimated completion is 2014-05.
What interventions are being tested in trial NCT02049164?
The interventions under investigation include: Placebo (DRUG), AR08 (DRUG).
Who is sponsoring clinical trial NCT02049164?
This trial is sponsored by Arbor Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.